These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1027487)

  • 41. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex.
    Sugi T; McIntyre JA
    Blood; 1995 Oct; 86(8):3083-9. PubMed ID: 7579402
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The subunit structure of normal and hemophilic factor VIII.
    Shapiro GA; Andersen JC; Pizzo SV; McKee PA
    J Clin Invest; 1973 Sep; 52(9):2198-210. PubMed ID: 4199414
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Blood kinins, their concentration in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen.
    Scicli AG; Mindroiu T; Scicli G; Carretero OA
    J Lab Clin Med; 1982 Jul; 100(1):81-93. PubMed ID: 6919569
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bovine plasma kininogens. II. Microheterogeneities of high molecular weight kininogens and their structural relationships.
    Komiya M; Kato H; Suzuki T
    J Biochem; 1974 Oct; 76(4):823-32. PubMed ID: 4474169
    [No Abstract]   [Full Text] [Related]  

  • 45. [Purification and some physico-chemical and enzymatic properties of tissue kallikrein from human urine].
    Rabinovich SE; Lobareva LS; Paskhina TS
    Biokhimiia; 1990 Sep; 55(9):1675-89. PubMed ID: 2078641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human high molecular weight kininogen as a thiol proteinase inhibitor: presence of the entire inhibition capacity in the native form of heavy chain.
    Higashiyama S; Ohkubo I; Ishiguro H; Kunimatsu M; Sawaki K; Sasaki M
    Biochemistry; 1986 Apr; 25(7):1669-75. PubMed ID: 3635411
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cleavage of human high-molecular weight kininogen by purified kallikreins and upon contact activation of plasma.
    Reddigari S; Kaplan AP
    Blood; 1988 May; 71(5):1334-40. PubMed ID: 2451949
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of high molecular weight kininogen on surface-adsorbed fibrinogen.
    Schmaier AH; Silver L; Adams AL; Fischer GC; Munoz PC; Vroman L; Colman RW
    Thromb Res; 1984 Jan; 33(1):51-67. PubMed ID: 6695362
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Isolation of two functionally different kininogens from human plasma--separation from proteinase inhibitors and interaction with plasma kallikrein.
    Habal FM; Movat HZ; Burrowes CE
    Biochem Pharmacol; 1974 Aug; 23(16):2291-303. PubMed ID: 4852592
    [No Abstract]   [Full Text] [Related]  

  • 50. Quantification of human high molecular weight kininogen by immunoblotting with a monoclonal anti-light chain antibody.
    Reddigari S; Kaplan AP
    J Immunol Methods; 1989 Apr; 119(1):19-25. PubMed ID: 2651524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Effect of kininogen on the activity of human blood serum kininogenase system].
    Datsenko VL; Iarovaia GA; Golosova NA; Lebedeva NV; Orekhovich VN
    Biokhimiia; 1977 Feb; 42(2):283-6. PubMed ID: 856307
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Accelerated assay, preservation and purification (concanavalin A) of plasma kininogen.
    Freedman HJ; Wilkens HJ; Back N
    Res Commun Chem Pathol Pharmacol; 1976 Nov; 15(3):581-99. PubMed ID: 996366
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High molecular weight kininogen is an inhibitor of platelet calpain.
    Schmaier AH; Bradford H; Silver LD; Farber A; Scott CF; Schutsky D; Colman RW
    J Clin Invest; 1986 May; 77(5):1565-73. PubMed ID: 2422211
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Purification of human low molecular weight kininogen and its application for a simple ND sensitive method for determination of human urinary kallikrein activity.
    Nakagawa M; Shimamoto K; Kondo M; Ura N; Nishitani T; Ishida H; Yokoyama T; Tanaka S; Iimura O
    Adv Exp Med Biol; 1986; 198 Pt B():523-9. PubMed ID: 3643739
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High molecular weight kininogen: its inability to correct the clotting of kininogen-deficient plasma after cleavage of bradykinin by plasma kallikrein, plasmin or trypsin.
    Chan JY; Movat HZ; Burrowes CE
    Thromb Res; 1979; 14(6):817-24. PubMed ID: 157559
    [No Abstract]   [Full Text] [Related]  

  • 56. Purification and properties of human low molecular weight kininogen.
    Müller-Esterl W; Vohle-Timmermann M; Boos B; Dittman B
    Biochim Biophys Acta; 1982 Sep; 706(2):145-52. PubMed ID: 6922723
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High molecular weight kininogen binds to unstimulated platelets.
    Gustafson EJ; Schutsky D; Knight LC; Schmaier AH
    J Clin Invest; 1986 Jul; 78(1):310-8. PubMed ID: 3722381
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of the procoagulant chain derived from human high molecular weight kininogen (Fitzgerald factor) by human tissue kallikrein.
    Maier M; Austen KF; Spragg J
    Blood; 1983 Aug; 62(2):457-63. PubMed ID: 6553501
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interaction of human low molecular weight kininogen with human mast cell tryptase.
    Schwartz LB; Maier M; Spragg J
    Adv Exp Med Biol; 1986; 198 Pt A():105-11. PubMed ID: 3544712
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Turnover of human and monkey plasma kininogens in rhesus monkeys.
    Yamada T; Wing DA; Pierce JV; Pettit GW
    J Clin Invest; 1979 Jan; 63(1):45-52. PubMed ID: 105015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.